Concepedia

R. Camisasca

RC

10

Publications

1.5K

Citations

10

H-Index

1998

Active since

Affiliations

Novartis (Switzerland)(Current)

Novartis (United States)

Tris Pharma (United States)

Baylor College of Medicine

Vita-Salute San Raffaele University

R. Camisasca is an author at Novartis (Switzerland) specializing in medicine, pharmacology, and metabolic syndrome.

Top concepts

Publications per year

1998–2014

10

Publications

10

Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Emanuele Bosi, R. Camisasca, C. Collober et al. · Diabetes Care · 2007 · 445 citations · Full text

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes

Julio Rosenstock, S. W Kim, Michelle A. Baron et al. · Diabetes Obesity and Metabolism · 2007 · 258 citations · Full text

Pharmacologic Demonstration of the Synergistic Effects of a Combination of the Renin Inhibitor Aliskiren and the AT1 Receptor Antagonist Valsartan on the Angiotensin II–Renin Feedback Interruption

Michel Azizi, Joël Ménard, Alvine Bissery et al. · Journal of the American Society of Nephrology · 2004 · 234 citations

, , +15

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*

A. J. Garber, James E. Foley, Mary Ann Banerji et al. · Diabetes Obesity and Metabolism · 2008 · 232 citations

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2‐year study

Stefano Del Prato, R. Camisasca, Candy Wilson et al. · Diabetes Obesity and Metabolism · 2014 · 81 citations · Full text

Rows per page

1–5 of 10